Drug Type Small molecule drug |
Synonyms 左氧氟沙星地塞米松, NTC010 |
Mechanism Bacterial DNA gyrase inhibitors, GR agonists(Glucocorticoid receptor agonists), Top II modulators(Topoisomerase II modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date DE (28 May 2020), |
Regulation- |
Molecular FormulaC18H22FN3O5 |
InChIKeyQEHPHWRZQAZOTI-PPHPATTJSA-N |
CAS Registry138199-71-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cataract | CA | 12 Dec 2023 | |
Eye Infections, Bacterial | CA | 12 Dec 2023 | |
Ocular inflammation | DE | 28 May 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Eye Infections | Phase 2 | - | - |
Phase 3 | 808 | (Levofloxacin + Dexamethasone Followed by Dexamethasone) | ywrrtemxnb(bndvvnqpbp) = giidfhzalg crbbrmjyxx (qnkkrpcjal, yhqhgljstw - wnpzobgnnb) View more | - | 18 Aug 2020 | ||
(Tobramycin + Dexamethasone) | ywrrtemxnb(bndvvnqpbp) = swhcxfxbaj crbbrmjyxx (qnkkrpcjal, jcixrordeq - vgxpnixqnz) View more | ||||||
Phase 2 | 125 | (Levofloxacin + Dexamethasone) | rdzgrieuvu(ptbzhsreot) = nuwzwzoiay kdnrnpejfh (irxntzaqaq, uvhorslwnu - ciyzeqblnj) View more | - | 07 Jul 2020 | ||
(Levofloxacin) | rdzgrieuvu(ptbzhsreot) = dnigjnfjov kdnrnpejfh (irxntzaqaq, ldqcjpdxpl - jcfpsgyfpt) View more |